1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  

This page is powered by Blogger. Isn't yours?

Saturday, August 19, 2017

 

Early Detection of Alzheimer’s through Retinal Scan






























The burden of Alzheimer’s disease (AD) goes far beyond the afflicted patient, affecting family, friends, and a significant portion of the healthcare system. Currently, there are more than 5 million individuals living with AD in the U.S., incurring $259 billion in healthcare costs. With costs estimated to rise to $1.1 trillion by 2050 as the number of AD cases could surpass 16 million, it is imperative that diagnostic tests be developed to detect early warning signs that signal the onset of the disease—at the very least to allow patients and their family time to prepare for various eventualities.        

Now, a team of neuroscientists at Cedars-Sinai have developed a noninvasive eye scan that could potentially detect the key signs of AD years before patients experience symptoms. Findings from the study—published recently in JCI Insight in an article entitled “Retinal Amyloid Pathology and Proof-of-Concept Imaging Trial in Alzheimer’s Disease”—showed that investigators were able to detect the buildup of amyloid-beta (Aβ) protein on the retina of AD patients. The results from this new study represent a major advancement toward identifying people with an elevated risk for the debilitating condition years sooner.

"The findings suggest that the retina may serve as a reliable source for Alzheimer's disease diagnosis," explained senior study author Maya Koronyo-Hamaoui, Ph.D., associate professor in the departments of neurosurgery and biomedical sciences at Cedars-Sinai. "One of the major advantages of analyzing the retina is the repeatability, which allows us to monitor patients and potentially the progression of their disease."

Interestingly, the researchers noted that another key finding was the discovery of amyloid plaques in previously overlooked peripheral regions of the retina. The authors pointed out that the plaque amount in the retina correlated with plaque amount in specific areas of the brain. “Now we know exactly where to look to find the signs of AD as early as possible," remarked lead study author Yosef Koronyo, M.Sc., a research associate in the department of neurosurgery at Cedars-Sinai.

"Our hope is that eventually the investigational eye scan will be used as a screening device to detect the disease early enough to intervene and change the course of the disorder with medications and lifestyle changes," added co-senior study investigator Keith Black, M.D., chair of Cedars-Sinai's department of neurosurgery and director of the Maxine Dunitz Neurosurgical Institute.

For decades, the only way to officially diagnose AD was to survey and analyze a patient's brain after the patient died. In recent years, physicians have relied on positron emission tomography (PET) scans of the brains of living people to provide evidence of the disease. However, this technology is expensive and invasive, requiring the patient to be injected with radioactive tracers.

For the current study, the researchers conducted a clinical trial on 16 AD patients who drank a solution that includes curcumin, a natural component of the spice turmeric. The curcumin causes amyloid plaque in the retina to "light up" and be detected by the scan. The patients were then compared to a group of younger, cognitively normal individuals.

“Burden, distribution, cellular layer, and structure of retinal Aβ plaques were analyzed in flat mounts and cross-sections of definite AD patients and controls (n = 37),” the authors wrote. “In a proof-of-concept retinal imaging trial (n = 16), amyloid probe curcumin formulation was determined and protocol was established for retinal amyloid imaging in live patients.”

The authors added that “histological examination uncovered classical and neuritic-like Aβ deposits with increased retinal Aβ42 plaques (4.7-fold; P = 0.0063) and neuronal loss (P = 0.0023) in AD patients versus matched controls. Retinal Aβ plaque mirrored brain pathology, especially in the primary visual cortex (P = 0.0097 to P = 0.0018; Pearson’s r = 0.84–0.91).”

To find a more cost-effective and less invasive technique, the Cedars-Sinai team collaborated with investigators at NeuroVision Imaging, the Commonwealth Scientific and Industrial Research Organization (CSIRO), the University of Southern California, and UCLA to translate their noninvasive eye screening approach to humans.

The investigators were excited by their findings and are in the process of expanding their study to incorporate a much larger number of subjects. 


Story Source: The above story is based on materials provided by GENETICENGINEERING&BIOTECHNOLOGYNEWS
Note: Materials may be edited for content and length